Remimazolam for Postoperative Sleep in Elderly Patients

Official record

Identifier

NCT07740343

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

Remimazolampropofol

Lead sponsor

General Hospital of Ningxia Medical University

Target enrolment

84 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Not yet recruiting

First posted

Jul 31, 2026

Last updated on the registry

Jul 31, 2026

Age

65 Years – 80 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Aged between 65 and 80 years.
* Scheduled for elective laparoscopic radical resection of colorectal cancer.
* American Society of Anesthesiologists (ASA) physical status class II-III.
* Able to understand the study protocol and provide written informed consent.

Exclusion Criteria:

* Known allergy to any study medications.
* Preoperative sleep disorder (Pittsburgh Sleep Quality Index \[PSQI\] score \> 10).
* Regular use of sedatives, antipsychotics or hormonal drugs within the past month.
* Preoperative cognitive impairment, screened using the education-adjusted Mini-Mental State Examination (MMSE).
* Preoperative history of neurological or psychiatric disorders, including Alzheimer's disease, Parkinson's disease, depression and anxiety disorders.
* Severe preoperative comorbidities involving the cardiovascular, cerebrovascular, respiratory, hepatic or renal systems, as follows:New York Heart Association (NYHA) functional class IV; current or recent (within 2 months) congestive heart failure; myocardial infarction or coronary stent implantation within the preceding 3 months; Uncontrolled frequent ventricular premature beats (\>5 beats per minute), couplets, triplets, paired ventricular arrhythmias, multifocal ventricular premature beats, or R-on-T phenomenon; Second-degree atrioventricular block (Mobitz II type), third-degree atrioventricular block or sick sinus syndrome without pacemaker implantation; Stroke or transient ischemic attack within the preceding 3 months; Severe hypertension (blood pressure ≥ 180/110 mmHg); Severe respiratory tract infection (including common cold), or maximal voluntary ventilation (MMV) \< 30% of the predicted value; Severe hepatic dysfunction (Child-Pugh score \> 9); Acute or chronic renal failure without renal replacement therapy: Acute kidney injury was defined as an absolute increase in serum creatinine ≥ 0.3 mg/dL (≥26.5 μmol/L) or a relative increase ≥ 50% from baseline, or urine output \< 0.5 mL/(kg·h) for more than 6 consecutive hours. Chronic renal failure or uremia was defined as serum creatinine \> 451 μmol/L and estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m².
* Severe coagulation disorders.
* Refusal to participate in the trial.
* Anticipated postoperative admission to the intensive care unit (ICU).